Approved for use through 33 17357, Ch8 563 C03.1

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1935, no persons are required to respond to a collection of information unless it displays a valid Otals control number.

			THE UNITED STATES	ATTORNEY'S DOCKET NUMBER PC26223A						
			OFFICE (DO/EO/US) IN UNDER 35 U.S.C. 371	U.S. APPLICATION NO. (If known, see 37 CFR 1.5)						
INTERNATIONAL APPLICATION NO.			INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED						
PCT/IB2004/003707			November 10, 2004	November 24, 2003						
TITLE OF INVENTION										
Quinolonecarboxylic Acid Compounds Having 5-HT4 Receptor Agonistic Activity										
APPLICANT(S) FOR DO/EO/US										
Tomoki KATO, Kiyoshi KAWAMURA, Mikio MORITA, Chikara UCHIDA Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:										
1.		· · · · · · · · · · · · · · · · · · ·								
2.	Ħ	This is a FIRST submission of items concerning a submission under 35 U.S.C. 371. This is a SECOND or SUBSECUENT submission of items constraint a submission under 35 U.S.C. 471.								
	Ħ	This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371. This is an expressive request to begin noticed promisetion promotives (25 U.S.C. 371/0). The submission must include								
3.	(2)	This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.								
4.		The US has been elected (Article 31).								
5.	\boxtimes									
	A copy o	grants.	ration as filed (35 U.S.C. 371(c)(2))							
	а.	is attached h	tereto (required only if not communicate	ated by the International Bureau).						
	b.	has been communicated by the International Bureau.								
	¢.	is not require	ed, as the application was filed in the	United States Receiving Office (RO/US).						
6.		An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).								
	3.	is attached hereto.								
	b.	has been previously submitted under 35 U.S.C. 154(d)(4).								
7.		Amendments to the cla	Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).							
	a.	are attached hereto (required only if not communicated by the International Bureau).								
	b.	have been communicated by the International Bureau.								
	c.	have not be	have not been made; however, the time limit for making such amendments has NOT expired.							
	d.	have not been made and will not be made.								
8.		An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 971(c)(3)).								
9.	\boxtimes	An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).								
10		An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).								
items 11 to 20 below concern document(s) or information included:										
11,		An Information Disclos	ure Statement under 37 CFR 1.97 an	d 1.98.						
12.		An assignment document for recording, A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.								
13	\boxtimes	A preliminary amendment.								
14		An Application Data Sheet under 37 CFR 1,76.								
15.		A substitute specification, 16, A power of attorney and/or change of address letter.								
16.		A power of attorney and/or change of address letter								
17.		A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825.								
18.		A second copy of the published International Application under 35 U.S.C. 154(d)(4).								
19.		A second copy of the	English language translation of the in	ternational application under 35 U.S.C. 154(d)(4).						

This obsection of information is required by 37 CFR 1.414 and 1.491-1.492. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 15 minutes to complete, including gathering information, preparing, and submitting the complete form to the USPTO Time will vary depending upon the including case. Any comments on the amount of time you require to complete his form and/or suggestions for recliping this burden, should be sent to the Chief Information Officer. U.S. Patent and Trademark Office, U.S. Deparament of Commerce, P.O. Box 1450, Alexandria, VA. 20313-1450, D.O. NOT SEND FIEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450.

Form PTC-1390 (Rev. 07-2005)

PTO-1350 (Rev. 97-2005)
Approved for use through 3/3 93097, OMS 0861-0001
U.S. Patent and Trademark Office, U.S. DISPARTMENT OF COMMISTICE
to a collection of information unless it displays a valid OMB control number.

U.S. APPLICATIO	N NO. (if known see 37 CFR	November 10, 2004		TORNEYS DOCKET NUMBER PC26223A		
20.	Other items or information					
The Following Fee	s have been submitted			CALCULATIONS	PTO USE ONLY	
21. 🔀 Bas	\$ 300.00					
22. Exar If the written opinio by IPEA All other situations	\$ 200.08					
23. If the written opinion by IPEA. Search fee (37 CF International Search previous All other situations	\$ 400.00					
	\$900.80					
Additions sequence The fee						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE	\$		
73-100 ≠	0/50=	0	x \$250	\$0		
Surcharge of \$130 after the date of co						
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	\$		
Total claim	s 14-20=	0	x \$50	\$0		
Independent claim		0	×\$200 +\$360	\$0		
MULTIPLE DEPEN	\$8					
	\$900.00					
Applican						
	\$900.00					
Processing fee of to claimed priority date						
	\$900.00					
Fee for recording to an appropriate cov						
· · · · ·	\$900.00					
	Amount to be refunded:	\$				
				Amount to be charged	s	

PTO-1390 (Rev. 97-2805) Approved for use through 3/31/2007, OMS 0861-0021

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperson's Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid CMB control number. A check in the amount of \$ to cover the above fees ins enclosed. \boxtimes ъ. Please charge my Deposit Account No. 16-1445 in the amount of \$900.00 to cover the above fees A duplicate copy of this sheet is enclosed. The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment C. to Deposit Account No. 16-1445. A duplicate copy of this sheet is enclosed. Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card d. information should not be included on this form. Provide credit card information and authorization on PTO-2038. NOTE: Where an appropriate time limit under 37 CFR 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the International Application to pending status. SEND ALL CORRESPONDENCE TO: Gregg C. Benson Pfizer Inc Eastern Point Road, MS 8260-1611 Groton, CT 06340 / Frank W Forman / SIGNATURE NAME - Frank W. Forman REGISTRATION NUMBER - 42,547